title: Should health care money in South Africa be spent on drotrecogin alfa?
authors.forename: Bettina
authors.initials: B
authors.lastname: Taylor
authors.forename: Derrick
authors.initials: D
authors.lastname: Burns
authors.forename: B W
authors.initials: BW
authors.lastname: van de Wal
authors.forename: Tony
authors.initials: T
authors.lastname: MBewu
authors.forename: G R
authors.initials: GR
authors.lastname: Keeton
mesh_terms: D000890:Anti-Infective Agents / Q000191:economics*; D002986:Clinical Trials as Topic; D003422:Critical Care / Q000191:economics; D005102:Health Expenditures; D006801:Humans; D011486:Protein C / Q000191:economics*; D011994:Recombinant Proteins / Q000191:economics*; D018805:Sepsis / Q000188:drug therapy*; D013019:South Africa; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated